Share Name Share Symbol Market Type Share ISIN Share Description
Alizyme LSE:AZM London Ordinary Share GB0000374289
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 4.08p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 8.17

Alizyme Share Discussion Threads

Showing 25926 to 25948 of 25950 messages
Chat Pages: 1038  1037  1036  1035  1034  1033  1032  1031  1030  1029  1028  1027  Older
DateSubjectAuthorDiscuss
01/4/2016
20:56
This year's update from the liquidators - hTTp://ww7.investorrelations.co.uk/alizyme/media/press/show.jsp?ref=170 Section on "Shareholders": 3.5. It is anticipated that there will be sufficient funds for a distribution to be made to the Company's shareholders. As stated in the annual report of ATL, future milestone payments may be received in 2016, thus facilitating a further distribution to the Company. 3.6. Given the uncertainty surrounding potential further dividends to the Company, I am unable to provide any estimates as to the timing or quantum of a distribution to the shareholders. 3.7. There are approximately 4,500 shareholders in the Company, thus it is not cost effective to pay an interim dividend, but the position will be reassessed in one year's time.
elgordo
18/2/2015
09:27
Nice that they are charging £256 per hour - or £500k per year for their effort. I wouldn't want to wind things up too quickly at that rate.
dr biotech
17/2/2015
18:41
Recent update. Shareholders may get something from the liquidation - but not yet!!!!! hxxp://ww7.investorrelations.co.uk/alizyme/media/press/show.jsp?ref=169
mikepearce45
28/4/2014
13:50
Thanks Mike for the update. I needed some good news after watching GKP and QPP share prices succumb to gravity!
mikepearce45
27/4/2014
18:04
Thanks for the update Mad mike.take care.
fidra
27/4/2014
16:30
I have only just come across AZM's Liquidator's reports dated 11-Feb-14 (on their web-site). For those that do not know, the important 'news' is litigation was settled last summer that had been holding up any possible realisation of assets for the benefit of shareholders. The Liquidator report says AZM shareholders will actually get something back for AZM their shares, though not immediately. Future dividend payments depend upon third parties' milestone/royalty payments. I believe there are around 217M AZM shares in issue, so it looks like every £1M of realised assets (after other creditors are paid off) would result in a shareholder payout of a little less than half a penny per share. The relevant section in the Liquidator's report is copied below. Also at the bottom there is a links to the Liquidator's Feb'04 reports:- "Shareholders [of Alizyme Plc] ~~~~~~~~~~~~ 3.5. It is anticipated that there will be sufficient funds for a distribution to be made to the Company's shareholders. As stated in the annual report of ATL, future milestone payments may be received in 2014, thus facilitating a further distribution to the Company. 3.6. Given the uncertainty surrounding potential further dividends to the Company, I am unable to provide any estimates as to the timing or quantum of a distribution to the shareholders. 3.7. There are approximately 4,500 shareholders in the Company, thus it is not cost effective to pay an interim dividend, but the position will be reassessed in one year's time." The Liquidator's 2013 annual reports for the following two companies can be found (n.b. these are different reports than those filed at Companies House):- hxxp://ww7.global3digital.com/alizyme/media/press/show.jsp?ref=168 - Alizyme Plc (the holding company that have the listed shares) - Alizyme Therapeutics Ltd (the subsidiary company holding the IPR & past activities).
mad mike
31/12/2013
13:02
From memory, I think that there was a faint possibility that should Cetilistat/Cametor/Oblean be successfully brought to market, that there was a possibility of future royalty payments to Alizyme/liquidators. I am not holding my breath though.
mikepearce45
30/12/2013
23:04
Blast from the past. I still remember turning up for the AGM and finding a note on the door saying we had gone into admin. The BOD were just not up for the job,
loafofbread
30/12/2013
04:55
yes, very annoying.Sold for a song as well. Thanks for the update mikepearce45.
fidra
30/12/2013
01:00
CAMETOR® Norgine has acquired the worldwide rights to CAMETOR (cetilistat). CAMETOR, also known as OBLEAN® in Japan, is being developed for the treatment of obesity with our partners Takeda, who are responsible for developing and marketing the product in Japan. On 30 September 2013 the Japanese Ministry of Health, Labour and Welfare approved the New Drug Application (NDA) of OBLEAN Tablets 120mg for the treatment of obesity with complications.
mikepearce45
01/11/2012
01:14
Great find but f£$%^ing annoying just the same.
billthebank
31/10/2012
15:15
Takeda Pharmaceutical submits NDA for obesity drug in Japan Comtex News Network Oct 31, 2012 (Datamonitor via COMTEX) -- Takeda Pharmaceutical Company Limited has submitted a new drug application, or NDA, to the Ministry of Health, Labour and Welfare, for cetilistat for the treatment of obesity with complications, in Japan. Cetilistat is a lipase inhibitor discovered by UK-based Alizyme Therapeutics Limited (Alizyme). The product inhibits the activity of lipase, a lipolytic enzyme, secreted by the digestive tract and pancreas, and blocks the absorption of fat from the gut, resulting in reduced body weight. Norgine acquired all rights to the product from Alizyme in October 2009. The NDA submission is based on the results of three Phase III clinical trials, a 52-week placebo-controlled to evaluate the efficacy and safety study, a 24-week and 52-week open-label safety study in obese patients with type 2 diabetes and dyslipidemia. The result of the efficacy study demonstrate that cetilistat 120mg three times daily was superior to placebo in the primary endpoint , reduction of average body weight, with -2.776% versus -1.103% with placebo. Greater reductions in HbA1c and LDL cholesterol were also observed in patients treated with cetilistat. All clinical trials demonstrated that cetilistat has a good safety profile and is well tolerated. Peter Stein, CEO of Norgine said "We are excited that this important new medicine may soon be available in Japan for patients who suffer from obesity, and its complications such as type 2 diabetes mellitus and dyslipidaemia. Norgine is looking forward to building on our excellent working relationship with our partners, Takeda." "Obesity is a disease with limited treatment options and thus has remarkable unmet medical need," said Nancy Joseph-Ridge, general manager of Takeda's Pharmaceutical development division. "If approved, cetilistat, with its novel mechanism of action, is expected to provide a welcomed new treatment option for physicians treating patients with obesity, with complications of both type 2 diabetes and dyslipidaemia in Japan." http://www.datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon
vow
18/7/2012
07:26
Administrators warn Alizyme shareholders . The administrators of stricken Cambridge UK biotech company Alizyme plc have warned shareholders to thoroughly investigate requests to buy their stock and not to hand over their bank details without proper due diligence. Ian Carr and Nigel Morrison, appointed when the company went bust in July 2009, have been forced into the unusual step of issuing the warning after being made aware that a number of shareholders were being approached with offers. Alizyme's administration was converted into a creditors' voluntary liquidation in December 2009 and the Grant Thornton partners are continuing to try to realise assets for creditors. But in an update issued today they alert Alizyme shareholders to be on their guard. A statement said: "In recent weeks, it has come to our attention that a number of shareholders are being approached with offers to purchase their shares. "It is not appropriate for the liquidators to advise the shareholders as to whether to enter into any correspondence with these offerors, or whether they should consider selling their shares to any other third party. "However, shareholders should always conduct appropriate investigations and due diligence into any offer made for their shares in order to satisfy themselves that it is a genuine good faith offer. "In circumstances where we understand that shareholders' bank details are requested as part of the offer process, it is not for us to comment on whether this is unusual or suspicious. "However, it is critically important for any individual shareholder to give serious consideration about this request for bank details to ensure that disclosure of such details, if any shareholders were minded to do so, would be appropriate and necessary and could not be misused." On the general situation, they added: "The liquidators continue to seek realisation of various assets and adjudication of certain significant claims. Until those two matters are more fully resolved it is not possible to advise on the likelihood of any return to shareholders." • PHOTOGRAPH SHOWS: Ian Carr
jeremye
18/7/2012
07:25
Administrators warn Alizyme shareholders . The administrators of stricken Cambridge UK biotech company Alizyme plc have warned shareholders to thoroughly investigate requests to buy their stock and not to hand over their bank details without proper due diligence. Ian Carr and Nigel Morrison, appointed when the company went bust in July 2009, have been forced into the unusual step of issuing the warning after being made aware that a number of shareholders were being approached with offers. Alizyme's administration was converted into a creditors' voluntary liquidation in December 2009 and the Grant Thornton partners are continuing to try to realise assets for creditors. But in an update issued today they alert Alizyme shareholders to be on their guard. A statement said: "In recent weeks, it has come to our attention that a number of shareholders are being approached with offers to purchase their shares. "It is not appropriate for the liquidators to advise the shareholders as to whether to enter into any correspondence with these offerors, or whether they should consider selling their shares to any other third party. "However, shareholders should always conduct appropriate investigations and due diligence into any offer made for their shares in order to satisfy themselves that it is a genuine good faith offer. "In circumstances where we understand that shareholders' bank details are requested as part of the offer process, it is not for us to comment on whether this is unusual or suspicious. "However, it is critically important for any individual shareholder to give serious consideration about this request for bank details to ensure that disclosure of such details, if any shareholders were minded to do so, would be appropriate and necessary and could not be misused." On the general situation, they added: "The liquidators continue to seek realisation of various assets and adjudication of certain significant claims. Until those two matters are more fully resolved it is not possible to advise on the likelihood of any return to shareholders." • PHOTOGRAPH SHOWS: Ian Carr
jeremye
18/2/2011
16:38
sorry mike, I should have said that I'd seen the tax credits stated in the docs you posted links to, but I was wondering if there was any tax asset against which profits could be offset ie. the tax losses. 'I don't believe you can sell tax losses.' near enough confirms it then, thanks. I still dont quite see what represents a 3rd party and what doesnt in M&A ie. if someone reversed into AZM, could they use the tax losses?
the_doctor
18/2/2011
16:28
anyone found out what the japanese cetillistat data showed? - it says they are discussing what further studies are needed, not discussing approval on the basis of it, so doesn't sound that great..
filbert3
18/2/2011
15:18
I still 'hold' 12000 of these. Wrote them off a long time ago. Good old Tim and his 'if I dont do a deal you can shoot me'... now where did I put my gun!
riskier
18/2/2011
13:23
Cheers for the update MM Your'e right they can't sell on the tax losses to 3rd parties. Going back some time there was a paid for brokers note on CEN that counted the tax loss as an asset worth 25p a share or similar. I remember thinking this was riduculous and needless to say CEN got sold for a fraction of that. Shame they can't be sold really, I'd like to get back 30% of the money I've lost on various biodogs.
dr biotech
18/2/2011
12:00
AZM/ATL have already received R&D tax credits, and are already in the assets I quoted. However it you really meant past tax losses (which would be huge), I believe you can only use such tax losses against future profits. Thus a profitable company would have to reverse into AZM/ATL to realises those past tax losses. Now that AZM/ATL are in liquidation I'm doubtful if anyone can reverse into them. FYI, I don't believe you can sell tax losses.
mad mike
18/2/2011
10:47
Interesting mad mike - and sad for holders of course, although something back is better than nothing! Any idea how tax credits are dealt with? ie. AZM had presumably built quite a lot up. Did that have any value, or is it not transferrable in that way?
the_doctor
18/2/2011
10:31
The liquidator's annual reports for Alizyme Plc, and its (important subsiduary) Alizyme Therapeutics Ltd can be found here:- http://www.alizyme.com/alizyme/media/press/show.jsp?ref=165 On a quick read (based upon current assets only), it looks like the most any Alizyme shareholder would receive is around 1.6p per share (n.b. these are my quick calculations so may be wrong, so please DYOR). My figure is just based upon £3.5M approx in current assets (after allowing for unsecured creditors), and 221M AZM shares in issue. However, even to get that payment a substaintial legal claim against the company would have to fail. Until that claim is resolved there can be no payout to unsecured creditors, let alone any payout to shareholders. Thus the claim must be substantial and likely to be in excess, of current assets i.e. greater than £3.5M. Possibly the only good news is Cetilistat has completed Phase III in Japan, & there are currently discussions about getting Market authorisation there. By good news, I'm making the unproven assumption that the current owners of Cetilistat (Norgine B.V.) could be making some payment to Alizyme if Cetilistat starts to get sold in Japan. The Annual report also announces an AGM for shareholders and creditors at 10:30am on 17/2/11, at Grant Thornton, 30 Finsbury Sq, London EC2P 2YU. Prior permission needs to be agreed before attending - see detials in Annual Report.
mad mike
18/2/2011
00:16
R we talking £100M liquidation value? How many shares were in issue?
billthebank
17/11/2010
16:13
So it this it? Its all over? I rode these from 27p to 140p back in 06 I think...Glad i'm out but feel for the holders who truely believed in this company.
royalt
Chat Pages: 1038  1037  1036  1035  1034  1033  1032  1031  1030  1029  1028  1027  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20161205 14:42:06